Literature DB >> 27687313

Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?

R Danesi1, M Del Re1, J Ciccolini2, J H M Schellens3, M Schwab4, R H N van Schaik5, A B P van Kuilenburg6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27687313     DOI： 10.1093/annonc/mdw448

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines.

Authors:  Elena De Mattia; Rossana Roncato; Chiara Dalle Fratte; Fabrizio Ecca; Giuseppe Toffoli; Erika Cecchin
Journal:  Cancer Drug Resist       Date:  2019-03-19

2.  UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS.

Authors:  Manon Launay; Joseph Ciccolini; Claire Fournel; Carmelo Blanquicett; Charlotte Dupuis; Nicolas Fakhry; Florence Duffaud; Sébastien Salas; Bruno Lacarelle
Journal:  Clin Cancer Drugs       Date:  2017

Review 3.  Pharmacogenetic testing in oncology: a Brazilian perspective.

Authors:  Guilherme Suarez-Kurtz
Journal:  Clinics (Sao Paulo)       Date:  2018-10-11       Impact factor: 2.365

4.  DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.

Authors:  Marzia Del Re; Saverio Cinieri; Angela Michelucci; Stefano Salvadori; Fotios Loupakis; Marta Schirripa; Chiara Cremolini; Stefania Crucitta; Cecilia Barbara; Angelo Di Leo; Tiziana Pia Latiano; Filippo Pietrantonio; Samantha Di Donato; Paolo Simi; Alessandro Passardi; Filippo De Braud; Giuseppe Altavilla; Claudio Zamagni; Roberto Bordonaro; Alfredo Butera; Evaristo Maiello; Carmine Pinto; Alfredo Falcone; Valentina Mazzotti; Riccardo Morganti; Romano Danesi
Journal:  Pharmacogenomics J       Date:  2019-02-06       Impact factor: 3.550

5.  DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

Authors:  Chiara Cremolini; Marzia Del Re; Carlotta Antoniotti; Sara Lonardi; Francesca Bergamo; Fotios Loupakis; Beatrice Borelli; Federica Marmorino; Valentina Citi; Enrico Cortesi; Roberto Moretto; Monica Ronzoni; Gianluca Tomasello; Alberto Zaniboni; Patrizia Racca; Angela Buonadonna; Giacomo Allegrini; Vincenzo Ricci; Samantha Di Donato; Vittorina Zagonel; Luca Boni; Alfredo Falcone; Romano Danesi
Journal:  Oncotarget       Date:  2017-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.